Engineering gut commensal bacteria to express heterologous proteins in their outer membrane vesicles (OMVs) for delivery to the GI-tract
This invention relates to the delivery of heterologous peptides or proteins such as therapeutic peptides, therapeutic proteins or antigens to mucosal sites using vesicles derived from the outer membrane of commensal bacteria, recombinant bacteria capable of producing such vesicles, and methods for the production of such vesicles. The invention further relates to an inducible expression system for use in recombinant bacteria.
1. A recombinant gram negative commensal gut bacterium from the Bacteroides genus comprising an expression system for expression of a heterologous peptide or protein in an outer membrane vesicle (OMV) wherein the expression system is an inducible gene expression system comprising:
a mannan-inducible promoter region of an alpha-1,2-mannosidase gene;
at least one ribosomal binding site;
a multiple cloning site; and
a transcriptional terminator.
2. The recombinant gram negative commensal gut bacterium as claimed in claim 1 wherein the heterologous peptide or protein is a therapeutic peptide, a therapeutic protein or an antigen.
3. The recombinant gram negative commensal gut bacterium as claimed in claim 1 wherein the heterologous peptide or protein is fused to the N-terminal signal peptide of an OMV-secreted protein.
4. A method for preparing an outer membrane vesicle (OMV) containing a heterologous peptide or protein, said method comprising:
generating a recombinant gram negative commensal gut bacterium from the Bacteroides genus that expresses a heterologous peptide or protein;
cultivating the bacterium under conditions that result in the expression of said heterologous peptide or protein and the production of OMV, wherein the expression is induced by a gene expression system comprising:
a mannan-inducible promoter region of an alpha-1,2-mannosidase gene;
at least one ribosomal binding site;
a multiple cloning site; and
a transcriptional terminator;
and isolating OMV thereby containing said heterologous peptide or protein.
5. The method as claimed in claim 4 wherein expression of the heterologous peptide or protein is inducible, preferably mannan-inducible.
6. The method as claimed in claim 5 wherein induction of the expression of the heterologous peptide or protein is delayed until OMV production.
7. The method as claimed in claim 5 wherein induction of the expression of the heterologous peptide or protein is tuned using varying concentrations of an inducing composition, such as mannan.
8. An OMV obtained from a bacterium from the Bacteroides genus as claimed in claim 1 .
9. A pharmaceutical composition comprising an OMV isolated from a recombinant gram negative gut bacterium from the Bacteroides genus as claimed in claim 1 .
10. The pharmaceutical composition as claimed in claim 9 further comprising a pharmaceutically acceptable excipient.
11. The pharmaceutical composition as claimed in claim 9 further comprising an adjuvant.
12. The recombinant gram negative commensal gut bacterium as claimed in claim 1 wherein the recombinant gram negative commensal gut bacterium is Bacteroides thetaiotaomicron (Bt).
13. The recombinant gram negative commensal gut bacterium according to claim 1 , wherein the heterologous peptide or protein is an antigen derived from Salmonella, Campylobacter or norovirus or is a therapeutic peptide or protein.
14. The method according to claim 4 , wherein the heterologous peptide or protein is an antigen derived from Salmonella, Campylobacter or norovirus, or is a therapeutic peptide or protein.
15. The OMV according to claim 8 , wherein the heterologous peptide or protein is an antigen derived from Salmonella, Campylobacter or norovirus, or is a therapeutic peptide or protein.
16. The pharmaceutical composition according to claim 9 , wherein the heterologous peptide or protein is an antigen derived from Salmonella, Campylobacter or norovirus, or is a therapeutic peptide or protein.